Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ALPN

Alpine Immune Sciences (ALPN)

Alpine Immune Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALPN
DateTimeSourceHeadlineSymbolCompany
12/04/202406:27PR Newswire (US)Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law FirmNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202421:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202406:15Business WireAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA NephropathyNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202406:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202406:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences Inc
02/04/202400:00Business WireAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024NASDAQ:ALPNAlpine Immune Sciences Inc
21/03/202422:45Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024NASDAQ:ALPNAlpine Immune Sciences Inc
21/03/202407:30Business WireAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
19/03/202407:05Business WireAlpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
08/03/202408:30Business WireAlpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
27/02/202408:30Business WireAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesNASDAQ:ALPNAlpine Immune Sciences Inc
15/02/202408:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
15/02/202401:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
08/02/202408:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
02/02/202408:30Business WireAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesNASDAQ:ALPNAlpine Immune Sciences Inc
23/01/202410:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
06/01/202410:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
06/01/202410:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
06/01/202408:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202411:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202411:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
22/12/202308:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
22/12/202308:15Business WireAlpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieNASDAQ:ALPNAlpine Immune Sciences Inc
19/12/202308:30Business WireAlpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
23/11/202302:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
21/11/202308:30Business WireAlpine Immune Sciences to Participate in the Evercore ISI HealthconX ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
16/11/202301:00Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
15/11/202308:15Business WireAlpine Immune Sciences Reports Third Quarter 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
14/11/202301:00Business WireAlpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
07/11/202313:41Business WireAlpine Immune Sciences Announces Pricing of $150 Million Public OfferingNASDAQ:ALPNAlpine Immune Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:ALPN